Prostate Cancer 18F-PSMA-1007 PET/CT Access Trial

Primary objective: • To determine if 18F-PSMA-1007 PET/CT imaging is effective at diagnosing prostate cancers and/or metastases compared to conventional imaging \[including CT, MRI, 99mTc-MDP Bone Scans as available\]. Secondary Objective: * To determine safety by evaluating for adverse events * To determine which conventional imaging is being performed when 18F-PSMA-1007 PET/CT imaging is available

NCT Number	NCT06489496
Lead Sponsor	Alberta Health services
Conditions	Prostate Cancer
Enrollment	1,000 participants
Start Date	2024-10-01
Primary Completion	2029-10-01 (estimated)
Study Completion	2030-10-01 (estimated)
Updated on ClinicalTrials.gov	2024-07-08